Recessive variants in ZNF142 cause a complex neurodevelopmental disorder with intellectual disability, speech impairment, seizures, and dystonia

Kamal Khan, MS1,2,3, Michael Zech, MD4,5, Angela T. Morgan, PhD6, David J. Amor, MBBS, PhD6, Matej Skorvanek, MD, PhD7,8, Tahir N. Khan, PhD1,17, Michael S. Hildebrand, PhD6,9, Victoria E. Jackson, PhD10, Thomas S. Scerri, MSc, DPhil10, Matthew Coleman, BA/BSc(Hons)9, Kristin A. Rigbye, BSc(Hons)9, Ingrid E. Scheffer, MBBS, PhD9,11, Melanie Bahlo, PhD10, Matias Wagner, MD4,5, Daniel D. Lam, PhD4,4, Riccardo Berutti, PhD12, Petra Havránková, MD, PhD13, Anna Fečíková, MD13, Tim M. Strom, MD5,12, Vladimir Han, MD7,8, Petra Dosekova, MD7,8, Zuzana Gdovinova, MD7,8, Franco Laccone, MD14, Muhammad Jameel, PhD2, Marie R. Mooney, PhD1, Shahid M. Baig, PhD2,3, Robert Jech, MD, PhD13, Erica E. Davis, PhD1, Nicholas Katsanis, PhD1 and Juliane Winkelmann, MD4,5,15,16

Purpose: The purpose of this study was to expand the genetic architecture of neurodevelopmental disorders, and to characterize the clinical features of a novel cohort of affected individuals with variants in ZNF142, a C2H2 domain-containing transcription factor.

Methods: Four independent research centers used exome sequencing to elucidate the genetic basis of neurodevelopmental phenotypes in four unrelated families. Following bioinformatic filtering, query of control data sets, and secondary variant confirmation, we aggregated findings using an online data sharing platform. We performed in-depth clinical phenotyping in all affected individuals.

Results: We identified seven affected females in four pedigrees with likely pathogenic variants in ZNF142 that segregate with recessive disease. Affected cases in three families harbor either nonsense or frameshifting likely pathogenic variants predicted to undergo nonsense mediated decay. One additional trio bears ultrarare missense variants in conserved regions of ZNF142 that are predicted to be damaging to protein function. We performed clinical comparisons across our cohort and noted consistent presence of intellectual disability and speech impairment, with variable manifestation of seizures, tremor, and dystonia.

Conclusion: Our aggregate data support a role for ZNF142 in nervous system development and add to the emergent list of zinc finger proteins that contribute to neurocognitive disorders.

Keywords: homozygosity mapping; developmental delay; ataxia; dolichocephaly; childhood apraxia of speech

INTRODUCTION
Zinc finger proteins (ZNF/zfp) comprise a diverse group of cellular effectors encoded by >1500 genes (HGNC database; https://www.genenames.org).1,2 ZNF/zfp contain different arrays of zinc finger domains, among which the Cys2His2 (C2H2) motif is abundant in eukaryotic genomes, and is found in >700 proteins (Fig. S1).1,2 The zinc finger proteins have established roles in the modulation of a wide range of cellular processes.2 The central and peripheral nervous systems seem to be susceptible to ZNF/zfp dysfunction: an accumulating list of pathogenic variants in ZNF/zfps have been reported in individuals affected by neurodevelopmental disorders, genetically and phenotypically diverse conditions impacting the central nervous system.3 For example, recessive variants in ZBTB11 cause a complex intellectual disability disorder accompanied by microcephaly, delayed motor milestones, facial hypotonia, and ataxia.4 Furthermore, several ZNF/zfps have been proposed to be the causative genes in genomic disorders. For example, de novo variants in ZBTB20 cause Primrose syndrome, offering genetic support of its involvement in the syndromic neurodevelopmental features of the 3q13.31 microdeletion syndrome.5-8 Additionally, loss-of-
Pathogenic variants in ZNF/zfp-encoding genes have also been reported in movement disorders, such as tremor and dystonia, clinical entities also considered to be neurodevelopmental disorders. Notably, recent studies have identified dystonia as one component of a complex disorder, Gabriele–de Vries syndrome, caused by haploinsufficiency in Yin and yang 1 (YY1), a C2H2 zinc finger transcription factor. However, variations in ZNF/zfps do not always impact cognitive function and can also cause isolated dystonia; for example, heterozygous missense variants as well as indels in THAP1/DYT6, a zinc finger protein with a conserved DNA-binding THAP domain, are associated frequently with dystonia in humans. The mechanisms by which pleiotropy is governed in ZNF/zfp disorders remains poorly understood; however, transcriptomic and CHIP-Seq experiments offer clues about the spatiotemporal effects of ZNF/zfp dysfunction. As one step toward addressing this question, RNA-seq of striatum and cerebellum from a Thap1 murine model showed dysregulation of pathways that are regulated in a tissue-dependent manner. In aggregate, ZNF/zfp transcription factors likely induce broad phenotypic consequences in accordance with expansive downstream target genes involved in development and homeostasis.

Here, we report four unrelated families comprising seven affected females with an overlapping neurodevelopmental disorder hallmarked by intellectual disability and speech impairment, variably expressive seizures, tremor, and dystonia. Investigators in four research centers independently performed exome sequencing (ES) in these families with undiagnosed conditions. In all cases, we identified recessive variants in ZNF142, encoding zinc finger protein 142, as a causal gene associated with the pathology.

MATERIALS AND METHODS

Ethics statement, recruitment, and subject evaluation

Clinical phenotyping, ES, and molecular analyses were approved by the relevant institutional ethics committees from participating centers (Munich, Germany; Prague, Czech Republic; Kosice, Slovakia; Vienna, Austria; Faisalabad, Pakistan; Durham, NC; Melbourne, Australia). Signed informed consent for study procedures and publication of clinical and genetic findings was obtained from all the participants or their legal representatives. For seven affected individuals, extensive clinical evaluation including medical history interviews, neurological and physical examinations, and review of chart records was performed. We obtained saliva (using Oragene kits) or peripheral blood samples from affected individuals and their healthy family members following standard venipuncture protocols, and we extracted DNA using standard phenol-chloroform methods or commercial kits: prepIT+L2P kit (DNA Genotek Inc, Ontario, Canada) for saliva and Qiagen QIAamp DNA Maxi Kit (Hilden, Germany) for blood. All participating research centers were connected through the public data sharing platform GeneMatcher (entry “ZNF142”).

Exome sequencing and variant analyses

Simplex, trio, quartet, or extended family-based exome sequencing (ES) (Fig. 1 and Fig. S2) was conducted using different commercial exome libraries and Illumina sequencing platforms; standard bioinformatics analyses are described in the Supplementary Data. Briefly, raw exome data were processed using standard read-mapping algorithms, aligner tools, quality control (QC) checks, and variant callers. Aligned reads were inspected with the Integrative Genomics Viewer (IGV, Broad Institute) and filtering of single-nucleotide and copy-number variants was conducted using objective criteria including variant type (e.g., nonsense, frameshift, missense), minor allele frequency (MAF) in relevant ethnicity-matched populations (e.g., gnomAD), in silico pathogenicity prediction tools (e.g., CADD, PolyPhen-2 for missense variants), and disease models (e.g., recessive, dominant, de novo).

Sanger sequencing

To verify candidate variants identified by ES and to test for segregation with disease, we performed bidirectional Sanger sequencing in all participating family members for whom DNA was available using BigDye Terminator chemistry on an ABI 3730 sequencer. Primer sequences are available upon request.

Homozygosity mapping (family C)

To identify homozygous regions shared between the two cases with ES data, we performed genome-wide homozygosity mapping. We generated a joint variant call file (vcf) of ES data using the GATK HaplotypeCaller and GenotypeGVCFs methods; this data set consisted of the two cases, the unaffected mother, and two healthy siblings. We used HomozygosityMapper to plot homozygosity stretches genome-wide using default parameters (Fig. 2a–c), and we used GeneDistiller 2014 and NCBI Genome Data Viewer to visualize the ZNF142 locus (Fig. 2c, d).

RESULTS

Clinical reports

Family A

Subject A-II-2 (Fig. 1a; Table 1) was born at term after an uncomplicated pregnancy; she is the second child of healthy unrelated parents of Slovakian descent. Although birth parameters and neonatal adaptation were normal, the parents reported feeding difficulties. She first presented to the clinic during her second year of life for developmental delay concerns. She sat at 12 months of age and started walking at 24 months, albeit with balance problems. Her speech development was impaired; she spoke her first 2–3 word
sentences at age 5. On at least one occasion, she suffered a
generalized tonic–clonic seizure that ceased spontaneously. By
the age of 4 years, she developed dystonic head posturing and
tremulous movements of the arms. Over time, abnormal
hyperkinetic movements, exaggerated during purposeful
motor activities, became a prominent disabling symptom.
Cognitive assessment at age 6 years revealed impaired mental
development, requiring special schooling. Behavioral testing
showed deficits in social domains and executive functions.
Routine laboratory studies and additional examinations
including cerebrospinal fluid analysis, electroencephalography,
and tests for inborn errors of metabolism were
non-diagnostic. Genetic testing ruled out Angelman syndrome,
Rett syndrome, hereditary dystonia 1 and 6, and the most
common ataxia disorders. Karyotyping and chromosomal
microarray analyses were normal. A computed tomography
scan of the head did not reveal structural anomalies. At her
last clinical examination (age 33 years), subject A-II-2
displayed tremulous cervical dystonia, facial dyskinesia, action
and postural tremor in her upper limbs, and an ataxic gait. She
also had severe intellectual disability (IQ: 50) and
profound speech problems with restricted vocabulary. Physical
examination showed dolichocephaly.

Individual A-II-1 (Fig. 1a; Table 1) displayed a constellation
of symptoms resembling that of her younger sister, A-II-2.
Her medical history was marked by signs of global
psychomotor deficits, involving fine and gross motor skill
development (walking at 15 months with lower limb
incoordination); language (single words spoken at 5 years);
and limited socialization. She presented with hyperkinetic
movement abnormalities and gait disturbances since early
childhood. No seizures have been documented. Multiple
biochemical assays and routine molecular testing all gave
normal results. At her most recent clinical evaluation at 35
years of age, subject A-II-1 demonstrated segmental cranio-
cervical dystonia, tremor of the head and upper limbs, gait
with no clear evidence of epileptiform discharges. Electroencephalography reported excessive beta activity, with no clear evidence of epileptiform discharges.

At the age of 2 years, she experienced an episode of tonic–clonic seizures. At last clinical examination (eight years old), we noted generalized dystonia combined with bilateral choreatic movements and minor ataxic features. At last clinical examination (eight years old), we noted generalized dystonia combined with bilateral choreatic movements and minor ataxic features. There was still no expressive language, but she showed evidence of verbal comprehension. Craniofacial examination detected no specific dysmorphic signs.

**Family B**
Subject B-II-1 (Fig. 1b; Table 1) was the only child born to consanguineous Turkish parents following an uneventful full-term pregnancy. There were no reported perinatal problems and growth parameters were within normal limits. The postnatal interval was characterized by feeding difficulties and excessive crying. We noted a hyperkinetic movement disorder that became evident during the first year of life. She developed dystonic posturing of the neck, trunk, and all four limbs. We also saw a gradual progression of chorea-like movements of the arms. Additionally, all aspects of psychomotor development were delayed from early infancy. She achieved unsupported sitting, but she was never able to walk independently and was wheelchair bound. She was unable to speak, and she communicated using gestures. Although higher mental function was not formally assessed, her cognitive level was estimated to be moderately disabled. At the age of 2 years, she experienced an episode of tonic–clonic seizures. Electroencephalography reported excessive beta activity, with no clear evidence of epileptiform discharges.

Biochemical and metabolic markers were normal. Targeted genetic testing for mitochondrial disorders and hereditary dystonias did not yield any likely pathogenic variants. Brain magnetic resonance imaging (MRI) findings, which did not change appreciably over a five-year period (three to eight years of age), were nondiagnostic and consisted of non-specific, subtle signal intensities in the lateral aspect of the left thalamus, subcortical gyrus pre- and postcentralis, subcortical occipital area, and left putamen. At last clinical examination (eight years old), we noted generalized dystonia combined with bilateral choreatic movements and minor ataxic features. There was still no expressive language, but she showed evidence of verbal comprehension. Craniofacial examination detected no specific dysmorphic signs.

**Family C**
We evaluated three affected females and their healthy mother from an extended multigenerational consanguineous Pakistani family (Fig. 1c; Fig. S2; Table 1). The proband (C-IV-3), presented with severe intellectual disability at her last clinical assessment (aged 18 years). She was born healthy subsequent to a full-term pregnancy with no known environmental contributing factors; she sat independently at the age of six

![Genome-wide homozygosity mapping in family C using exome sequencing data.](image-url)

**Fig. 2** Genome-wide homozygosity mapping in family C using exome sequencing data. (a) Stretches of homozygosity were mapped on jointly called exome sequencing (ES) data from five individuals (two affected, two unaffected siblings, and their unaffected mother) using HomozygosityMapper software. Black vertical lines, regions with <80% homozygosity exclusive to cases; red vertical lines, regions with >80% homozygosity exclusive to cases. The blue arrow indicates a stretch of homozygosity on chr2 harboring the ZNF142 variant. (b) Enlarged view of chr2 indicating the homozygous genomic stretches shared between affected individuals. The blue dotted rectangle outlines the 10.6-Mb region of interest with a 100% homozygosity score. (c) Graphical representation of the homozygous region on chr2 generated with GeneDistiller. Blue, heterozygous variant calls; red, homozygous regions with lighter red to darker red reflecting shorter to longer homozygous stretches, respectively. (d) Ideogram of chr2 generated by Genome Data Viewer showing the position of ZNF142 (blue rectangle) at 2q35 (hg19: chr2: 219502640-219524355).
Table 1 Molecular and clinical characterization for seven individuals with biallelic variants in ZNF142

|                     | Family A | Family B | Family C | Family D |
|---------------------|----------|----------|----------|----------|
|                     | A-II-1   | B-II-1   | C-IV-3   | C-IV-7   | C-IV-8   | D-II-2   |
| Sex                 | Female   | Female   | Female   | Female   | Female   | Female   |
| Age at most recent  | 35 years | 33 years | 8 years  | 18 years | 13 years | 13 years |
| examination         |          |          |          |          |          |          |
| Ethnicity           | Slovakian| Slovakian| Turkish  | Pakistani| Pakistani| Pakistani|
| Family history      | Positive | Positive | Negative | Positive | Positive | Positive |
| Nucleotide          | c.817_818delAA; c.1292delG; compound heterozygous | c.3175C>T; homozygous | c.4183delC; 4185G>A; homozygous | c.3698G>T; c.4498C>T | c.1292delG; compound heterozygous |
| alteration           |          |          |          |          |          |          |
| (NM_001105537.2;    |          |          |          |          |          |          |
| inheritance)        |          |          |          |          |          |          |
| Protein alteration   | p.Lys273Glu*32; p.Cys431Leufs*11 | p.Lys273Glu*32; p.Cys431Leufs*11 | p.Arg1059* | p.Leu1395* | p.Leu1395* | p.Leu1395* |
| (NP.001099007.1)    |          |          |          |          |          |          |
| Neurodevelopment     |          |          |          |          |          |          |
| and function         |          |          |          |          |          |          |
| Developmental       |           |           |           |           |           |           |
| milestones           |           |           |           |           |           |           |
| Sit: 10 months;    |           |           |           |           |           |           |
| walk: 15 months     |           |           |           |           |           |           |
| Sit: 12 months;     |           |           |           |           |           |           |
| walk: 24 months     |           |           |           |           |           |           |
| Cognition           |           |           |           |           |           |           |
| Severe Impaired (IQ |           |           |           |           |           |           |
| 52)                |           |           |           |           |           |           |
| Severe Impaired (IQ |           |           |           |           |           |           |
| 50)                |           |           |           |           |           |           |
| Moderately impaired;|           |           |           |           |           |           |
| IQ not available    |           |           |           |           |           |           |
| Severe impaired     |           |           |           |           |           |           |
| WISC-R / FSIQ (59)  |           |           |           |           |           |           |
| Severe impaired     |           |           |           |           |           |           |
| WISC-R / FSIQ (40)  |           |           |           |           |           |           |
| Severe Impaired      |           |           |           |           |           |           |
| WISC-R / FSIQ (59)  |           |           |           |           |           |           |
| Severe Impaired      |           |           |           |           |           |           |
| WISC-R / FSIQ (40)  |           |           |           |           |           |           |
| Severe Impaired      |           |           |           |           |           |           |
| WISC-R / FSIQ (59)  |           |           |           |           |           |           |
| Speech               |           |           |           |           |           |           |
| Delayed: singular    |           |           |           |           |           |           |
| words at 5 years,   |           |           |           |           |           |           |
| last examination:   |           |           |           |           |           |           |
| cerebellar dysartria|           |           |           |           |           |           |
| with hypernasality, |           |           |           |           |           |           |
| restricted           |           |           |           |           |           |           |
| vocabulary          |           |           |           |           |           |           |
| Delayed: first 2–3   |           |           |           |           |           |           |
| word sentences at 6 |           |           |           |           |           |           |
| years; last         |           |           |           |           |           |           |
| examination:        |           |           |           |           |           |           |
| spastic speech with  |           |           |           |           |           |           |
| severely            |           |           |           |           |           |           |
| impaired speech     |           |           |           |           |           |           |
| initiation,          |           |           |           |           |           |           |
| restricted           |           |           |           |           |           |           |
| vocabulary          |           |           |           |           |           |           |
| (No speech) no       |           |           |           |           |           |           |
| expressive language, |           |           |           |           |           |           |
| verbal              |           |           |           |           |           |           |
| comprehension intact|           |           |           |           |           |           |
| Delayed speech;      |           |           |           |           |           |           |
| unable to speak in   |           |           |           |           |           |           |
| full sentences       |           |           |           |           |           |           |
| Delayed speech;      |           |           |           |           |           |           |
| unable to speak in   |           |           |           |           |           |           |
| full sentences       |           |           |           |           |           |           |
| Receptive and        |           |           |           |           |           |           |
| expressive speech    |           |           |           |           |           |           |
| delayed             |           |           |           |           |           |           |
| Childhood apraxia    |           |           |           |           |           |           |
| of speech            |           |           |           |           |           |           |
| Movement disorder    |           |           |           |           |           |           |
| characteristics and  |           |           |           |           |           |           |
| other neurological   |           |           |           |           |           |           |
| features             |           |           |           |           |           |           |
| Dystonia (age of     | Segmental (4 years) | Segmental (4 years) | Generalized (1 year) | – | – | – |
| onset)               |           |           |           |           |           |           |
| Dystonia site of     | Neck | Neck | Neck | NA | NA | NA |
| onset                |           |           |           |           |           |           |
| Areas involved in     | Face, neck, upper limbs | Face, neck, upper limbs | Face, neck, trunk, all 4 limbs | NA | NA | NA |
| dystonia (most recent|           |           |           |           |           |           |
| examination)         |           |           |           |           |           |           |
| Tremor               | + | + | – | – | + | + |
| Ataxia               | + | + | + | – | + | – |
months, and started walking at the age of one year. At the age of four months, she displayed her first seizures, which reoccurred seven to eight times during her first three years of life; these have since abated without any medical interventions. During her seizure episodes, she became unconscious for 10–20 minutes. At her last clinical assessment, she also presented with severe speech impairment. She displays dolichocephaly with a head circumference of 53 cm (within normal range for age, 51–57 cm).21 Her neurological assessment showed no symptoms of dystonia, ataxia, or tremors; MRI imaging of the brain showed no significant structural abnormalities.

The affected dizygotic twin female siblings in family C had similar features to the index case at last clinical assessment (aged 13 years). They presented with severe cognitive impairment and tonic–clonic seizures starting in the neonatal period (age 13 days). They were born healthy after a full-term pregnancy with no known teratogenic exposures, but shortly thereafter displayed developmental delay. They sat independently at the age of 15 months and started walking at 18 months. Individual C-IV-7 experiences seizures at variable frequency, ranging from twice a week to five to seven times per day with unknown triggering factors. The use of anticonvulsants stabilizes her condition during seizure episodes; however, the medications show no effect on the frequency of seizures. However, individual C-IV-8 displayed a total of seven to eight incidences of seizures in her lifetime. During these episodes, both affected twins became unconscious for 10–20 minutes. They also presented severe speech impairment and are unable to speak in full sentences. At their last clinical assessment, head circumference for both twins was within the normal range (C-IV-7, 53 cm; C-IV-8, 54 cm; normal, 49–55 cm),21 but C-IV-8 displayed dolichocephaly. Neurological assessment revealed ataxia and generalized tremors in C-IV-7, whereas C-IV-8 displayed tremors and no other neurological features; MRI was not performed for either individual.

Their mother (C-III-I) had normal cognitive function, reported that she met all her developmental milestones, and had not experienced seizures or any other neurological symptoms. The three affected females have five healthy siblings, and a sixth deceased sibling who experienced long-lasting seizure episodes ranging from a few minutes to a few hours and was deceased at the age of nine years after experiencing an overnight seizure attack (Fig. 1c; Fig. S2).

**Family D**

Subject D-II-2 is a 10-year-old girl, the second of three children born to healthy parents (Fig. 1d; Table 1). Her older sister and younger brother are healthy. She was born at term by forceps delivery after an uncomplicated pregnancy and there were no neonatal complications. Her early development was mildly delayed: she sat at 12 months and walked at 18 months and was slow to acquire language. At age 3 years she was diagnosed with delayed motor development and showed brisk reflexes in the lower limbs and tightening of the
calves, suggestive of mild spastic diplegia. The main developmental concern reported by the parents has been a severe and persistent speech disorder, namely childhood apraxia of speech, which was severe from ages 3 to 8 years and has only begun to resolve in the past two years. She attends regular school but neuropsychological assessment showed low average IQ (full scale IQ [FSIQ] 78). She has not had any major physical health problems, has not had seizures, and has normal hearing and vision. Height, weight, and head circumference are all at the 90th centile. On examination she was nondysmorphic and could walk and run. She had normal muscle power but was hyperreflexive in the lower limbs with sustained clonus and increased tone. Upper limb reflexes are relatively brisk. An MRI showed mild thinning of the posterior aspect of the body of the corpus callosum with associated mild reduction in white matter volume. Chromosome microarray was normal.

**Genomic studies identify rare biallelic variants in ZNF142**

To investigate the genetic basis of disease in family A, we performed ES in a quartet paradigm. We achieved an average target read depth ranging from 114× to 149× across the four individuals, with 98.2% to 98.9% of coding regions covered by ≥20 reads (Table S1). Subsequent to our bioinformatic filtering criteria, we identified a single candidate gene, ZNF142, bearing likely pathogenic compound heterozygous variants that segregated with the phenotype. Both affected siblings (A-II-1 and A-II-2, Fig. 1a; Table 1; Table S2) harbored variants predicted to cause a frameshift; these included a 2-bp deletion (NM_001105537.2: c.817_818delAA; p.Lys273Glufs*32) and a 1-bp deletion (c.1292delG; p.Cys431Leufs 11; Fig. 1a, e, i) predicted to undergo nonsense mediated decay. We confirmed these results using bidirectional Sanger sequencing. Neither variant was reported in public databases (>140,000 individuals in ExAC and gnomAD v2.1) or our in-house control ES data collections (10,000 individuals).

We next considered the known biological function of ZNF142 (Fig. S1). It is a predicted transcription factor expressed ubiquitously across adult tissues, with the highest expression reported in the brain, specifically the cerebellum (GTEx Portal; gtexportal.org). This gene has not been implicated previously in human genetic disorders, but a mouse mutant with homozygous ablation of the orthologous locus (Zfp142) has behavioral and neurological phenotypes (Mouse Genome Informatics and the International Mouse Phenotyping Consortium [IMPC]; MGI refID: J:211773).

Next, we queried ZNF142 in our in-house exome database ($n=10,000$ individuals with various neurological and non-neurological phenotypes of diverse ethnicities; Munich). We identified an individual affected with neurodevelopmental deficits who had no previously established genetic diagnosis (family B; B-II-1; Fig. 1b; Table 1). She had a homozygous nonsense variant (c.3175C>T; p.Arg1059*) predicted to truncate the latter half of the polypeptide (Fig. 1b, f, i; Table 1; Table S2). We validated this finding with Sanger sequencing in the trio; the variant segregated in an autosomal recessive fashion from heterozygous carrier parents. The nonsense change, albeit rare, was documented in the NCBI database (rs546151500) and was also reported in two heterozygous individuals in gnomAD (MAF: 8.022 × 10−6).

Reanalysis of the family B proband’s ES data identified an additional rare homozygous variant in a known human disease gene, SLC19A3 (NM_025243.3: c.952G>A; p.Ala318Thr; Table S2), disruption of which causes autosomal recessive thiamine metabolism dysfunction syndrome 2 (THMD2; MIM 607483).22 THMD2 is hallmarked by recurrent bouts of subacute encephalopathy, often progressing to coma and death in early childhood.22 The SLC19A3 change, which we confirmed by Sanger sequencing, was located in a contiguous homozygous stretch that also contained the ZNF142 variant. Further, the p.Ala318Thr variant was absent from gnomAD v2.1, and absent from morbid human gene databases, and thus categorized as a variant of uncertain significance (VUS). To investigate a possible contribution of the SLC19A3 change to phenotype, we performed repeated brain MRI evaluation, but observed no degenerative processes or signal alterations as they are found typically in individuals with THMD2. Moreover, empirical treatment of B-II-1 with high doses of biotin/thiamine, which is known to ameliorate cases with LOF variants in SLC19A3,22,23 resulted in no clinical improvement thereby reducing further the likelihood of this locus as a major phenotype contributor. We identified pathogenic homozygous variants in two different known disease-causing genes (GMMPB and MUT), but both loci cause non–phenotype overlapping recessive conditions (Table S3).

To identify molecular lesions that might contribute to the pathology of family C, we conducted ES on six individuals (Fig. 1c; Fig. S2). We obtained a mean target coverage of 67–91× with 94% of bases covered >20× for all individuals (Table S1). Based on the recurrence of similar phenotypes (four of nine siblings; Fig. 1c; Table 1) and unaffected consanguineous parents, we posited an autosomal recessive mode of inheritance. First, we performed homozygosity mapping with ES data. We recalled variants among the five individuals from the same branch of the pedigree jointly (C-III-1, C-IV-1, C-IV-3, C-IV-4, and C-IV-7), and identified homozygous genomic regions shared between affected individuals. As expected, all four siblings displayed homozygosity consistent with previous reports for consanguineous pedigrees (9–14%) (ref. 24). We identified four homozygous stretches localized to chromosomes 2, 7, 10, and 16 with >80% of the maximal homozygosity score (Fig. 2a). Among these regions, the segment on chr2q was the only region to achieve the maximal homozygosity score (Fig. 2a–d). This region contains three blocks encompassing 10.6 Mb (chr2:214012405-224620246; hg19), contains 340 homozygous markers, and includes 84 protein-encoding genes.

Independently of the homozygosity analysis, we prioritized rare (MAF <1%) functional variants that were either homozygous or compound heterozygous and shared between...
affected individuals. There were no loci with compound heterozygous variants fulfilling these criteria. However, we found rare homozygous changes present in two genes, RUFY4 and ZNF142, both present within the region on 2q35 identified by homozygosity mapping. First, we considered the missense variant in RUN and FYVE domain containing 4 (RUFY4; NM_198483.3: p.Asn194Ile; Table S2). Although this variant is present at MAF 0.01% in gnomAD (320/280,382 alleles), it is enriched in the South Asian population (MAF = 1.03%, including three individuals in homozygosity). Due to the high frequency of this variant in the South Asian population, we considered it unlikely to cause the pathology.

Next, we turned our attention to the homozygous likely pathogenic variant in ZNF142, encoding p.Leu1395*, which is the combination of a deletion and a substitution (c.4183delC +c.4185G>A; Table S2). The deletion variant (c.4183delC) results in substitution of leucine to tryptophan and subsequent frameshift (p.Leu1395Trpfs*2) and the substitution (c.4185G>A) is a synonymous variant. Neither change is present in homozygosity in gnomAD, and each variant is found in heterozygosity once in >249,000 alleles. Segregation analysis in 17 available family members from the pedigree demonstrate that these two changes are in cis (Fig. 1c, g; Fig. S2). The variant is predicted to truncate 292 amino acids from the C-terminal encoding region of the putative protein (Fig. 1i), removing 9 of 31 DNA-binding C2H2-type domains, and is likely pathogenic.

To uncover the genetic cause of pathology in family D, we filtered variants from ES data (Table S1) of the trio (unaffected parents D-I-1 and D-I-2, and affected proband II-2). We filtered ES data for de novo variants, and no likely deleterious changes met our filtering criteria (Table S3). Next, analysis of the ES data following a recessive paradigm did not identify homozygous variants, however, we identified compound heterozygous variants in ZNF142 (Table S2): c.3698G>T (p.Cys1233Phe) inherited from the father (D-I-1) and c.4498C>T (p.Arg1500Trp) inherited from the mother (D-I-2) (Fig. 1d, h). Both variants are present in public databases in heterozygosity (1 of 249,582 and 4 of 280,716 alleles in gnomAD, respectively), but homozygotes have not been reported for either change. Both variants reside in C2H2-type zinc finger domains (Fig. 1i) and are predicted to impact the function of ZNF142 (PolyPhen-2 scores: 0.998 and 0.999; SIFT scores: 0 and 0.005; and CADD scores: 31 and 26, respectively). Sanger analysis showed that variants segregate with disease (Fig. 1d, h).

**DISCUSSION**

Here, we report four unrelated families with seven affected females who exhibit overlapping clinical features and harbor likely pathogenic recessive variants in ZNF142. We conducted investigations that include (1) recruitment and clinical evaluation of patients with neurodevelopmental disorders and their family members, (2) pedigree-based ES and bioinformatic filtering, (3) genome-wide homozygosity mapping (family C, Fig. 2a–d), and (4) community-wide data sharing. The LOF variants identified in families A, B, and C are predicted to result in premature stop codons; we expect the resulting products to be targeted for degradation through nonsense mediated decay or, less likely, to lead to the generation of truncated proteins that lack functional C2H2 domains. The missense variants identified in family D localize to the conserved regions of ZNF142 and are predicted to be pathogenic (Fig. S3; Table S2).

The families described in this study were assessed as part of research projects with differing phenotypic foci (families A and B, movement disorders; family C, syndromic intellectual disability; family D, childhood apraxia of speech). However, reverse phenotyping revealed that all affected individuals had a strikingly similar course of their illness. Unifying symptoms of the disorder include moderate to severe cognitive impairment (7/7), speech deficits (7/7), motor impairment (7/7), variably penetrant tonic–clonic seizures (5/7), tremor (4/7), and dystonia (3/7). The complex phenotypic traits can potentially be explained by the widespread roles of ZFN/zfps, which impact the regulation of diverse neuronal pathways and function;1,4,17,27 we do not know whether observed variable expressivity in our patients is the product of genetic background differences or stochastic factors. Additional families with pathogenic variants at this locus will be required to understand the range of ZNF142-related phenotypes. We also note that the family B proband had a more severe presentation in terms of movement disorder and motor incoordination in comparison with other cases. She harbors a homozygous VUS in SLC19A3 in addition to the ZNF142 variant. We speculate that an additive or epistatic effect between the two loci might contribute to the observed clinical severity, although there are currently no known interactions between the two genes that support this possibility.

Our work expands the functional role of ZNF/zfps in neurodevelopment, however, the precise mechanisms through which ZNF142 impacts neuronal function are unclear. Although ZNF142 is part of the largest subgroup of ZNF/zfps (Fig. S1), it does not have a recent common structure with most other C2H2 family members. To investigate the relationship of ZNF142 to other genes that cause neurodevelopmental disorders, we performed a multiple sequence alignment of 492 of the 720 C2H2 proteins in the HGNC database that had UniProt/SwissProt annotations using COBALT.28 We examined protein similarities based on (1) the 492 annotated family members and (2) the ZNF142 adjacent branches. We found that of the 492 annotated C2H2 subgroup members, 58 (18%) are linked to clinical synopses (Table S4; OMIM; https://www.omim.org/). Additionally, 67% of OMIM-associated genes are involved in neurodevelopmental disorders. Notably, three of the four closest subfamily members to ZNF142 have been implicated in syndromic intellectual disability (Fig. 3b; Table S4).29–31 For example, recessive missense variants in ZNF407 result in cognitive impairment, hypotonia, dysmorphic features, and digit defects.30
It is conceivable that lack of ZNF142 may alter spatiotemporally controlled transcriptional programs. This has been shown for THAP1, wherein genes involved in eIF2α signaling, neuron projection development, axonal guidance signaling, synaptic long-term depression, and mitochondrial dysfunction were reported to be dysregulated significantly.17 Future studies on downstream target genes in patient cell lines or in vivo systems will shed light on roles played by ZNF142 and promote an understanding of the molecular pathogenesis of disease. Although we recognize that a limitation of our study is the small cohort size, we predict that the condition is underidentified in clinical practice. ZNF142 molecular testing in individuals manifesting with a phenotypic spectrum overlapping speech impairment, epilepsy, and movement disorder will likely improve the ability to perform improved clinical and molecular studies.

SUPPLEMENTARY INFORMATION
The online version of this article (https://doi.org/10.1038/s41436-019-0523-0) contains supplementary material, which is available to authorized users.
ACKNOWLEDGEMENTS

We are grateful to the patient families for their engagement and support of our research. We thank J. Willer for assistance with ES library prep (family C). This work was supported by grants from the National Institutes of Health (5P01DK096415 to N.K. and MH106826 to E.E.D.). This study was funded in part by the Czech Science Foundation (GACR16-13323S) as well as in-house institutional funding from Technische Universität München, Munich, Germany; Helmholtz Zentrum München, Munich, Germany; and Charles University, Prague, Czech Republic (PROGRES Q27). This study was also supported by the Slovak Grant and Development Agency under contract APVV-14-0415 to M.S., V.H., and Z.G. Additionally, K.K. was funded by an International Research Support Initiative Program fellowship from the Higher Education Commission of Pakistan. M.Z. was supported by an internal research program at Helmholtz Center Munich, Germany (Physician Scientists for Groundbreaking Projects). D.D.L. was supported by DFG grant LA 3830/1-1. This work was also supported by Australian National Health & Medical Research Council (NHMRC) Project (ID: 1127144) and Centre of Research Excellence (ID: 1116976) grants to A.T.M., and the Victorian Government’s Operational Infrastructure Support Program and NHMRC Independent Research Institute Infrastructure Support Scheme (NHMRC IRIISS) to M.B. A.T.M. was supported by NHMRC Practitioner Fellowship 1105008. M.B. was supported by an NHMRC program grant (ID: 1054618) and NHMRC Senior Research Fellowship (ID: 1102971). M.S.H. was supported by an NHMRC Career Development Fellowship (ID: 1063799).

DISCLOSURE

N.K. is a paid consultant for and holds significant stock in Rescindo Therapeutics, Inc. The other authors declare no conflicts of interest.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES

1. Cassandri M, Smirnov A, Novelli F, et al. Zinc-finger proteins in health and disease. Cell Death Discov. 2017;3:17071.
2. Laity JH, Lee BM, Wright PE. Zinc finger proteins: new insights into structural and functional diversity. Curr Opin Struct Biol. 2001;11:39–46.
3. Sun Y, Hu D, Liang J, et al. Association between variants of zinc finger genes and psychiatric disorders: systematic review and meta-analysis. Schizophr Res. 2015;162:124–137.
4. Fattahi Z, Sheikhi T, Muante L, et al. Biallelic missense variants in ZBTB11 can cause intellectual disability in humans. Hum Mol Genet. 2018;27:3177–3188.
5. Cordeddu V, Redeker B, Schlueter M, et al. Mutations in ZBTB20 cause Primrose syndrome. Nat Genet. 2005;37:593–599.
6. Ikonomou G, Houlend H, Scarmeas N, et al. THAP1 mutations and dysonstia phenotypes: genotype-phenotype correlations. Mov Disord. 2012;27:1290–1294.
7. Zakirova Z, Fanuza T, Bonet J, et al. Mutations in THAP1/DYT6 reveal that diverse dysonstias genes disrupt similar neuronal pathways and functions. PLoS Genet. 2018;14:e1007169.
8. Sobrera N, Schiettecatte F, Valle D, et al. Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum Mutat. 2015;36:928–930.
9. Van der Auwera GA, Carneiro MO, Hartl C, et al. From FastQ to data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013;43:11 10–11–33.
10. Seelow D, Schuelke M, Hildebrandt F, et al. Mutations in zinc finger proteins in consanguineous individuals with autosomal recessive disease. Am J Hum Genet. 2005;77:16–26.
11. Lindeboom RG, Supek F, Lehrer B. The rules and impact of nonsense-mediated mRNA decay in human cancers. Nat Genet. 2016;48:1112–1118.
12. Bradshaw NJ, Porteous DJ. DISC1-binding proteins in neural development, signalling and schizophrenia. Neuropharmacology. 2012;62:1230–1241.
13. Papadopoulos JS, Agarwala R. COBALT: constraint-based alignment tool for multiple protein sequences. Bioinformatics. 2007;23:1241.
14. Hempel M, Cremer K, Ockeloen CW, et al. De novo mutations in CHAMP1 cause intellectual disability with severe speech impairment. Am J Hum Genet. 2015;97:493–500.
15. Kambouris M, Maroun RC, Ben-Omran T, et al. Mutations in zinc finger 407 (ZNF407) cause a unique autosomal recessive cognitive impairment syndrome. Orphanet J Rare Dis. 2014;9:80.
16. Tolkowski ME, Rosenfield JA, Blumenthal I, et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell. 2012;149:525–537.

microdeletion 3q13.31 syndrome. Eur J Med Genet. 2016;59:463–469.
12. Baxter AL, Vivian JL, Hagelstrom RT, et al. A novel partial duplication of ZEB2 and review of ZEB2 involvement in Mowat-Wilson syndrome. Mol Syndromol. 2017:8:211–218.
13. Yuan H, Zhang L, Chen M, et al. A de novo triplication on 2q22.3 including the entire ZEB2 gene associated with global developmental delay, multiple congenital anomalies and behavioral abnormalities. Mol Cytopigenet. 2015;8:99.
14. Buraniqi E, Moodley M. ZEB2 gene mutation and duplication of 2q11.23 in Mowat-Wilson syndrome. J Child Neurol. 2015;30:32–36.
15. Ghouri M, Drevillon L, Alavi-Naini SM, et al. ZEB2 zinc-finger missense mutations lead to hypermorphic alleles and a mild Mowat-Wilson syndrome. Hum Mol Genet. 2013;22:2652–2661.
16. Domingo A, Erro R, Lohmann K. Novel dystonia genes: clues on disease mechanisms and the complexities of high-throughput sequencing. Mov Disord. 2016;31:471–477.
17. Gabriele M, Vulto-van Silfhout AT, Germain PL, et al. YY1 haploinsufficiency causes an intellectual disability syndrome featuring transcriptional and chromatin dysfunction. Am J Hum Genet. 2017;100:907–925.
18. Fuchs T, Gavarini S, Saunders-Pullman R, et al. Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. Nat Genet. 2009;41:286–288.
19. Kervestin S, Jacobson A. NMD: a multifaceted response to premature translational termination. Nat Rev Mol Cell Biol. 2012;13:700–707.
20. Xiromerisiou G, Houlden H, Scarmeas N, et al. THAP1 mutations and dystonia phenotypes: genotype-phenotype correlations. Mov Disord. 2012;27:1290–1294.
21. Doolin L, Stellacci E, Stellacci E, et al. Mutations in ZBTB20 cause Primrose syndrome. Nat Genet. 2014;46:288.
22. Nellhaus G. Head circumference from birth to eighteen years. Practical composite international and interracial graphs. Pediatrics. 1968;41:106–114.
23. Zeng WQ, Al-Yamani E, Acienro JS Jr., et al. Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. Am J Hum Genet. 2005;77:16–26.
24. Debis R, Djeppine C, Rastetter A, et al. Biotin-responsive basal ganglia disease in ethnic Europeans with novel SLC19A3 mutations. Arch Neurol. 2010;67:126–130.
25. Woods CG, Cox J, Springell K, et al. Quantification of homogyzosity in consanguineous individuals with autosomal recessive disease. Am J Hum Genet. 2006;78:889–896.
26. Vervestin S, Jacobson A. NMD: a multifaceted response to premature translational termination. Nat Rev Mol Cell Biol. 2012;13:700–712.
27. Lindeboom RG, Supek F, Lehrer B. The rules and impact of nonsense-mediated mRNA decay in human cancers. Nat Genet. 2016;48:1112–1118.
28. Bradhaw NJ, Porteous DJ. DISC1-binding proteins in neural development, signalling and schizophrenia. Neuropharmacology. 2012;62:1230–1241.
29. Papadopoulos JS, Agarwala R. COBALT: constraint-based alignment tool for multiple protein sequences. Bioinformatics. 2007;23:1073–1079.
30. Kambouris M, Maroun RC, Ben-Omran T, et al. Mutations in zinc finger 407 (ZNF407) cause a unique autosomal recessive cognitive impairment syndrome. Orphanet J Rare Dis. 2014;9:80.
31. Tolkowski ME, Rosenfield JA, Blumenthal I, et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell. 2012;149:525–537.
1Center for Human Disease Modeling, Duke University Medical Center, Durham, NC, USA. 2Human Molecular Genetics Laboratory, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan. 3Pakistan Institute of Engineering and Applied Sciences (PIEAS), Islamabad, Pakistan. 4Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany. 5Institut für Humangenetik, Technische Universität München, Munich, Germany. 6Murdoch Children’s Research Institute and University of Melbourne Department of Paediatrics, Royal Children's Hospital, Parkville, Australia. 7Department of Neurology, P.J. Safarik University, Kosice, Slovak Republic. 8Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovak Republic. 9Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, VIC, Australia. 10Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, and University of Melbourne Department of Medical Biology and School of Mathematics and Statistics, Parkville, VIC, Australia. 11University of Melbourne Department of Paediatrics, Royal Children’s Hospital, and Florey and Murdoch Children’s Research Institute, Parkville, VIC, Australia. 12Institut für Humangenetik, Helmholtz Zentrum München, Munich, Germany. 13Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General Faculty Hospital, Prague, Czech Republic. 14Institute of Medical Genetics, Medical School of Vienna, Vienna, Austria. 15Lehrstuhl für Neurogenetik, Technische Universität München, Munich, Germany. 16Munich Cluster for Systems Neurology, SyNergy, Munich, Germany. 17Present address: Department of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan